Followers | 144 |
Posts | 27606 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
![](https://investorshub.advfn.com/uicon/33650.png?cb=1628859195)
Thursday, August 11, 2005 6:12:34 AM
11.8.2005 / 12:35
TheMarker
Lehman Brothers today repeated an Equal Weight rating for Syneron (TASE, Nasdaq:ELOS), after raising its forecasts for the company following its strong second-quarter financial statement.
For the year 2005, analyst Bob Hopkins expects the Israeli medical-laser technology company to report $1.39 earnings per share, up from $1.14 for 2004 and rising to $1.78 in 2006. Compared with his previous estimates, the change upward is about 25%.
His estimates remain below the Wall Street consensus, however.
For the year 2005, Hopkins now estimates Syneron will present $84.3 million in revenue, an increase of $4 million. For the year 2006, he's looking at $110.4 million in recommendation, up $4.7 million from his former projection. Much of the change is due to expected strong sales of the company's cellulite treatment device, Vela, especially from 2006.
Lehman's 12-month price target is $40, based on 23 times estimated 2006 earnings per share of $1.78, Hopkins writes.
Dubi
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM